RVMD Revolution Medicines

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.

Details of the company’s participation are as follows:

  • Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

    Conference Dates: February 7-8, 2024

    Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, February 7, 2024

    Location: New York, NY; webcast available
  • TD Cowen 44th Annual Health Care Conference

    Conference Dates: March 4-6, 2024

    Fireside Chat Time/Date: 2:10 p.m. Eastern on Wednesday, March 6, 2024

    Location: Boston, MA; webcast available

To access the live webcasts of the presentations, please visit the “Events & Presentations” page of Revolution Medicines’ website at . Additionally, replays of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following each conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).



Revolution Medicines Media & Investor Contact:
Erin Graves
650-779-0136
EN
01/02/2024

Underlying

RVMDRevolution Medicines

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Revolution Medicines

David Nierengarten ... (+5)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
XNCR XENCOR INC.
NVCR NOVOCURE LTD.
FATE FATE THERAPEUTICS INC
MRSN MERSANA THERAPEUTICS
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ACET ADICET BIO INC
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
GLUE MONTE ROSA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
05/23/25 May 23, 2025 1 EN
 PRESS RELEASE
Free
RVMD Revolution Medi...

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical...

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236), a RAS(ON) mul...

May 14, 2025 1 EN
Wedbush Research
  • Wedbush Research
GEO GEO GROUP INC. (THE)
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FB FACEBOOK INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
INOD INNODATA
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
SNDK SANDISK CORPORATION
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ZG ZILLOW GROUP INC. CLASS A
ESTC ELASTIC N.V.
SAFE SAFEHOLD INC.
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
RVMD INC.
GBIO REVOLUTION MEDICINES
U GENERATION BIO
RKT UNITY SOFTWARE
ABNB ROCKET COMPANIES
AI AIRBNB INC. CLASS A
PLTR C3.AI
VRDN PALANTIR TECHNOLOGIES
NUVB VIRIDIAN THERAPEUTICS INC
SNOW NUVATION BIO INC (A)
STX SNOWFLAKE INC. CLASS A
APP SEAGATE TECHNOLOGY HLDGS PLC
CCSI APPLOVIN CORP
GFS CONSENSUS CLOUD SOLUTIONS INC
ALCC GLOBALFOUNDRIES INC
DBD ALTC ACQUISITION CORP
NOW-US DIEBOLD NIXDORF INCORPORATED
SERVICENOW
INC.
05/08/25 May 8, 2025 1 EN
Ritika Das ... (+2)
  • Ritika Das
  • Robert Driscoll
RVMD REVOLUTION MEDICINES
05/08/25 May 8, 2025 1 EN
 PRESS RELEASE
Free
RVMD Revolution Medi...

Revolution Medicines Reports First Quarter 2025 Financial Results and ...

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch